Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.
CNBC -

The deal would allow J&J to resolve the lawsuits through a third bankruptcy filing of a subsidiary company, LTL Management.

Related Articles

Latest in News

More from CNBC | Breaking News: Business Johnson & Johnson Health care industry Pharmaceuticals Biotech and Pharmaceuticals Biotechnology Business business news cnbc Articles US: News Companies Business News Health & Science source:tagname:CNBC US Source Talc Ovarian cancer